This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant of $274,547 awarded to Life Seal Vascular Inc. on July 1, 2024 aims to develop a novel aneurysm sealing device (ASD) for endovascular applications. The project seeks to address the limitations of current treatments for abdominal aortic aneurysms (AAA) by creating a device that can completely seal the aneurysm sac, reducing the risk of post-procedure complications. The research objectives include validating the device's adaptability to different aneurysm profiles and compatibility with various aortic locations to ensure broad patient applicability. The technical approach involves a compressible body unit designed for precision deployment and a dual function that allows for drug delivery post-deployment. The anticipated outcomes include demonstrating the device's effectiveness in sealing aneurysms in a benchtop flow model, which could pave the way for potential regulatory approval. This project represents a significant advancement in AAA treatment, offering a more reliable and versatile solution compared to existing endovascular methods.
Generated 3/4/25, 7:26 AM